Mirabegron is still covered by patents covering ... Several copycat versions of the drug have already been approved, including from Zydus Cadila and Lupin Labs. However, given Astellas’ plan ...

Cost prevents patients from switching to preferred beta-3 agonists. Mirabegron was the only beta-3 agonist eligible for the Centers for Medicare/Medicaid Services (CMS) 2023 Drug Negotiation Program ...

The BEST trial will compare mirabegron (an oral medication) to BOTOX® (a medication injected into the bladder) for treating urgency urinary incontinence (UUI). UUI is when you feel a sudden, strong ...

The purpose of this study is to fill the evidence gap with direct-comparison data on patient-important efficacy and safety outcomes between an oral medication (Mirabegron or Vibegron) versus Botox A® ...